Thrive Earlier Detection’s New Paradigm for Cancer Screening

article image

Thrive Earlier Detection’s eye-catching debut underscores the tantalizing reality that one of liquid biopsy’s most ambitious projects, a multi-cancer blood screening test, might be achievable, but even with the involvement of veteran scientists and executives, the start-up has a lot to prove.

The debut of Thrive Earlier Detection Corp. last spring was hard to miss: a molecular diagnostics company with a stated goal of curing cancer by diagnosing it at the earliest stages, starting life with a team of world-renowned scientific founders and a $110 million Series A.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: